Advisors Asset Management Inc. Has $782,000 Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Advisors Asset Management Inc. boosted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 7.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,856 shares of the medical research company’s stock after purchasing an additional 852 shares during the quarter. Advisors Asset Management Inc.’s holdings in Edwards Lifesciences were worth $782,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the business. First Community Trust NA bought a new position in shares of Edwards Lifesciences during the 2nd quarter worth about $29,000. Webster Bank N. A. bought a new stake in shares of Edwards Lifesciences in the 2nd quarter worth approximately $39,000. Versant Capital Management Inc lifted its position in shares of Edwards Lifesciences by 206.3% in the 2nd quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock worth $45,000 after acquiring an additional 326 shares during the period. Prospera Private Wealth LLC acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter worth approximately $32,000. Finally, Avior Wealth Management LLC increased its position in shares of Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares during the period. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Stock Up 0.4 %

Shares of EW opened at $71.56 on Wednesday. The business’s fifty day moving average price is $67.83 and its two-hundred day moving average price is $75.37. The firm has a market capitalization of $42.20 billion, a price-to-earnings ratio of 10.33, a PEG ratio of 3.96 and a beta of 1.12. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.67. The business had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.59 earnings per share. On average, analysts predict that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Oppenheimer reissued an “outperform” rating and issued a $90.00 price target on shares of Edwards Lifesciences in a report on Thursday, September 12th. JPMorgan Chase & Co. upped their target price on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Robert W. Baird cut their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Canaccord Genuity Group lowered their price objective on Edwards Lifesciences from $66.00 to $63.00 and set a “hold” rating on the stock in a research note on Friday, October 25th. Finally, Evercore ISI cut their target price on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. Seventeen analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $75.67.

Insider Activity at Edwards Lifesciences

In related news, insider Larry L. Wood sold 25,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total transaction of $347,550.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,262,521.36. This represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 40,000 shares of company stock worth $2,657,000 over the last ninety days. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.